1 Min Read
Oct 4 (Reuters) - Therapeuticsmd Inc:
* Phase 3 topline data NDA submission for TX-004HR expected in Q4 2017 Source text: (bit.ly/2yX9sek) Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.